(Q51553487)

7 April 2018

title

In vitro and in vivo antioxidant properties of gliclazide. (English)

1 reference

7 April 2018

author name string

O'Brien RC

1

1 reference

7 April 2018

Luo M

2

1 reference

7 April 2018

Balazs N

3

1 reference

7 April 2018

Mercuri J

4

1 reference

7 April 2018

publication date

1 July 2000

1 reference

7 April 2018

Journal of Diabetes and its Complications

published in

1 reference

7 April 2018

volume

14

1 reference

7 April 2018

issue

4

1 reference

7 April 2018

page(s)

201-206

1 reference

7 April 2018

Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Free radical activity in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Diabetes mellitus and macrovascular complications. An epidemiological perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Tissue sulfhydryl groups

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Diabetes mellitus and serum carotenoids: findings from the Third National Health and Nutrition Examination Survey.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Melatonin and taurine reduce early glomerulopathy in diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Catalysis of lipid peroxidation by glucose and glycosylated collagen

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: Clinical assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

The role of oxidation and glycation in the pathogenesis of diabetic atherosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Gliclazide: a general free radical scavenger

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Determination of ascorbic acid in human vitreous humor by high-performance liquid chromatography with UV detection

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

High rat food vitamin E content improves nerve function in streptozotocin-diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Lipid peroxidation in proliferative vitreoretinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

Abnormalities of ascorbic acid metabolism and diabetic control: differences between diabetic patients and diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900084-2

7 January 2021

10.1016/S1056-8727(00)00084-2

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

11004429

1 reference

7 April 2018